-
公开(公告)号:US20220072010A1
公开(公告)日:2022-03-10
申请号:US17527910
申请日:2021-11-16
申请人: Nektar Therapeutics
IPC分类号: A61K31/573 , C07J41/00 , A61K47/60 , A61K47/59
摘要: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.
-
公开(公告)号:US11007270B2
公开(公告)日:2021-05-18
申请号:US16592702
申请日:2019-10-03
申请人: Nektar Therapeutics
IPC分类号: A61K31/404 , C07D209/34 , A61K47/54 , A61K47/60
摘要: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
-
公开(公告)号:US10512644B2
公开(公告)日:2019-12-24
申请号:US16165364
申请日:2018-10-19
申请人: Nektar Therapeutics
IPC分类号: A61K31/485 , C07D489/04 , A61K31/439 , C07D489/02 , A61K31/402 , A61K31/4025 , A61K31/4468 , A61K47/10 , A61K47/60
摘要: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
-
公开(公告)号:US10434181B2
公开(公告)日:2019-10-08
申请号:US15908286
申请日:2018-02-28
申请人: Nektar Therapeutics
IPC分类号: C07C237/44 , A61K47/59 , A61K31/166 , C07C231/12 , A61K47/60
摘要: The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
-
公开(公告)号:US20190247388A1
公开(公告)日:2019-08-15
申请号:US16393383
申请日:2019-04-24
申请人: Nektar Therapeutics
IPC分类号: A61K31/485 , A61K31/4468 , A61K31/4025 , A61K31/402 , C07D489/02 , A61K47/60 , A61K47/10 , A61K31/439
CPC分类号: A61K31/485 , A61K31/402 , A61K31/4025 , A61K31/439 , A61K31/4468 , A61K47/10 , A61K47/60 , C07D489/02
摘要: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
-
公开(公告)号:US20190046523A1
公开(公告)日:2019-02-14
申请号:US16165364
申请日:2018-10-19
申请人: Nektar Therapeutics
IPC分类号: A61K31/485 , A61K31/4468 , A61K31/4025 , A61K31/402 , C07D489/02 , A61K47/60 , A61K47/10 , A61K31/439
CPC分类号: A61K31/485 , A61K31/402 , A61K31/4025 , A61K31/439 , A61K31/4468 , A61K47/10 , A61K47/60 , C07D489/02
摘要: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
-
公开(公告)号:US10189859B2
公开(公告)日:2019-01-29
申请号:US15106741
申请日:2014-12-19
申请人: Nektar Therapeutics
发明人: Pankaj Sharma , Vijay Kumar Khatri , Xuyuan Gu , Yuan Song , Michael Lixin Shen , Jennifer Riggs-Sauthier , Neel K. Anand , Antoni Kozlowski , Aleksandrs Odinecs , Timothy A. Riley , Zhongxu Ren , YongQi Mu , Xiaoming Shen , Xuejun Yuan , Natalia Aurrecoechea , Donogh John Roger O'Mahony , Bo-Liang Deng
IPC分类号: C07D253/075 , C07D403/04 , C07D401/04 , A61K31/53 , A61K31/496 , A61P25/02 , A61P25/18 , A61P33/06 , C07D498/04 , A61P25/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D471/10
摘要: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
-
公开(公告)号:US10143690B2
公开(公告)日:2018-12-04
申请号:US15791951
申请日:2017-10-24
申请人: Nektar Therapeutics
IPC分类号: C07D489/02 , A61K31/485 , A61K47/10
摘要: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
-
公开(公告)号:US20180256599A1
公开(公告)日:2018-09-13
申请号:US15788626
申请日:2017-10-19
申请人: Nektar Therapeutics
IPC分类号: A61K31/573 , C07J41/00
CPC分类号: A61K31/573 , A61K47/59 , A61K47/60 , C07J41/0005
摘要: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.
-
公开(公告)号:US09375486B2
公开(公告)日:2016-06-28
申请号:US14428816
申请日:2013-09-17
申请人: Nektar Therapeutics
IPC分类号: C07C231/12 , C07C237/44 , A61K47/48 , A61K31/166
CPC分类号: A61K47/59 , A61K31/166 , A61K47/60 , C07C231/12 , C07C237/44
摘要: The invention relates to (among other things) oligomer-containing benzamide-based compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
摘要翻译: 本发明涉及(尤其是)含有低聚物的苯甲酰胺类化合物。 本发明的化合物相对于缺乏低聚物的相应化合物显示出一个或多个优点。
-
-
-
-
-
-
-
-
-